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Patients with peritoneal or local metastases from colorectal cancer have a poor prognosis. However, aggressive treatments by
debulking surgery and infusional intraperitoneal (i.p.) chemotherapy have been tried and appear to benefit selected patients. We
assayed the effects of debulking surgery and i.p. chemotherapy with respect to survival and compared the results with matched
control patients treated by intravenous (i.v.) chemotherapy. In all, 18 patients with peritoneal and/or local metastases from colorectal
adenocarcinoma underwent debulking surgery followed by 5-fluorouracil (5-FU) 550mgm
 2day
 1 i.p. and leucovorin (LV)
60mgm
 2day
 1 i.v. The chemotherapy was started the day after surgery and was given daily for 6 days and repeated monthly for
totally eight courses. The control patients, matched for age, gender, performance status and metastatic site, were randomly selected
from controlled clinical chemotherapy trials and treated with i.v. 5-FUþLV or i.v. methotrexateþ5-FUþLV. There was no
treatment-related mortality. The median survival among i.p. patients was 32 months compared to 14 months in the control group. In
all, 11 patients who underwent macroscopically radical surgery had a longer survival than those who were not radically operated
(P¼0.02). These results indicate that patients with peritoneal metastases and/or locally advanced cancers but without distant
metastases may benefit from cytoreductive surgery combined with i.p. chemotherapy.
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Peritoneal or local metastasis from colorectal cancer implies a poor
prognosis (Graf et al, 1991; Mahteme et al, 1996; Shepherd et al,
1997; Assersohn et al, 1999) and the treatment remains a
challenging problem. Moreover, patients with peritoneal carcino-
matosis often suffer from intestinal obstruction and nutritional
deficit (van Ooijen et al, 1993; Mahteme et al, 1996). In the absence
of more effective therapeutic options, systemic 5-fluorouracil (5-
FU)-based chemotherapy, irinotecan or oxaliplatin is used in order
to achieve a regression of the tumour and improved outcome
(Ragnhammar et al, 2001; Glimelius, 2003). Previous studies have
demonstrated that chemotherapy prolongs survival about 4–6
months compared with supportive care alone (Colorectal Cancer
Collaborative Group, 2000). The median survival time in patients
with peritoneal carcinosis treated with modern chemotherapy is in
the order of 6–12 months (de Gramont et al, 2000). Intraperitoneal
(i.p.) 5-FU infusion has been suggested as an alternative route of
administration with the purpose to expose peritoneal and local
tumour remnants to high cytotoxic drug levels (Cunliffe and
Sugarbaker, 1989), while only small amounts pass into systemic
circulation. In recent years, there have been reports on i.p.
chemotherapy treatment after cytoreductive surgery (Schellinx
et al, 1996; Horsell et al, 1999; Culliford et al, 2001). A median
survival of about 30 months was recently reported in patients
treated with cytoreductive surgery plus i.p. chemotherapy (Elias
et al, 2001).
The aim of this study was to explore the effects of cytoreductive
surgery followed by repeated courses of i.p. chemotherapy with
respect to feasibility, side effects and survival, and to compare with
the results obtained using systemic chemotherapy.
PATIENTS AND METHODS
Patients characteristics
In all, 18 patients (nine women, nine men, mean age 54 years,
range 31–74) were included in the study. The study was approved
by the regional ethics committees. The protocol was set up in 1991
and the last patient was included in September 1999. The inclusion
criteria were primary colorectal adenocarcinoma (colon 16, rectal
2), with local or peritoneal tumour deposits either resectable or
suitable for debulking surgery, and without hepatic or other extra
abdominal tumour growth as judged from laparotomy, chest X-ray
and ultrasonography/CT scan, age o75 years and American
Society of Anesthesiologists (ASA) classification grades 1–2.
Informed consent was obtained from each patient. The diagnosis
of the primary tumour and the metastases were verified
histopathologically. One patient was not treated according to the
protocol because of extensive irresectable peritoneal tumour
growth. The remaining 17 patients were treated by either total
macroscopic removal (11) or debulking (6) of the metastases
followed by i.p. chemotherapy. In four patients, the diagnosis of
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llocal or peritoneal spread was carried out concomitant with the
diagnosis of the primary tumour, and in the remaining 14 patients
there was an interval of mean 19 (range 1–52) months between the
diagnosis of the primary tumour and the local/peritoneal
recurrence. A system for classification of local/peritoneal spread
was set up based on which all patients could be classified: (a)
predominant peritoneal growth7smaller local deposits; (b)
predominant local growth7smaller peritoneal deposits; and (c)
predominant abdominal wall growth7smaller local or peritoneal
deposits. Two patients were classified in group a, six in group b
and 10 in group c.
Surgical treatment
The mean operating time was 3.7h (range 0.9–6.7). The surgical
procedure, the metastatic location and the treatments are detailed
in Table 1. At the end of surgery, a PORT-A-CATH (No. 21-2000-
04, SIMS deltec, Inc., St Paul, MN, USA) was placed subcuta-
neously just above the periost of the lower ribs and a catheter was
tunnelled through the abdominal wall and directed towards the
principal tumour site. Finally, a drainage no. 18 was placed in the
abdominal cavity. The drainage was plugged while the chemother-
apy was given, but opened for drainage of peritoneal fluid for 1–
2h just before the next i.p. infusion. This drainage was removed at
the end of the first treatment course.
Intraperitoneal chemotherapy
The i.p. chemotherapy was started the day after surgery. 5-
Fluorouracil was given i.p. (550mgm
 2day
 1) dissolved in 500ml
saline 0.9%. At 60min after the start of the i.p. infusion, an i.v.
infusion of leucovorin (LV) (60mgm
 2) was administered. The
pharmacokinetical rationale for this sequential treatment is to
obtain simultaneous tissue peak concentration of 5-FU and LV
(Spears et al, 1989). The 5-FU dose was selected after a pilot study,
showing that an i.p. 5-FU dose of 550mgm
 2day
 1 during 6 days
was possible to give directly after major abdominal surgery
without causing an increased risk for postoperative complications
(Graf et al, 1994c). The chemotherapy treatment was given daily
for 6 days with 4–6 weeks intervals. Any possible symptoms and
side effects of the treatment were registered. Before the second
course of treatment, a single photon emission computed
tomography (SPECT) (General Electric, GE Maxxus, Milwaukee,
WI) (Technetium-labelled albumin (
99Tc
m Albures) at volume of
500ml) was performed to judge the potential distribution of the
drug in the abdominal cavity. The distribution of the drug was
calculated using a computer-based measurement (FBP, Nuclear
Diagnostics AB, Stockholm, Sweden). After the fourth course, a
clinical evaluation was carried out. Another run of four courses
was given if the patients responded well, tolerated treatment and
had no clinical signs of tumour progression. After the eighth
course, the patients were evaluated by clinical examination and CT
scans/MRI or a second look. In two patients, the choice of the i.p.
chemotherapy courses after the first one was based on in vitro
assessment of chemotherapy-resistance test (Csoka et al, 1995). In
these patients, i.p. cisplatin and i.p. irinotecan was given,
respectively. The i.p. treatment was given as an outpatient
procedure, except the first course, which was given directly after
surgery.
Control group
In all, 18 patients (nine women, nine men, mean age 56 years,
range 36–69) treated for advanced colorectal adenocarcinoma
within the Nordic chemotherapy trials (Nordic Gastrointestinal
Tumour Adjuvant Therapy Group, 1992; Glimelius, 1993; Glimelius
et al, 1998) were randomly selected as a reference group. The
selection was made without any knowledge of survival. The
selection criteria were: (1) resected primary colorectal adenocarci-
noma (colon 15, rectal 3); (2) local or peritoneal tumour deposits;
(3) no lymphatic, hepatic or extra abdominal tumour growth; (4)
Karnofsky performance status 480 (mean 90, range 80–100); (5)
treated by intravenous (i.v.) chemotherapy (eight patients received
MFL and 10 received FLv). Furthermore, the control group was
matched according to age and gender. The metastatic sites in this
group were as follows: peritoneal (5), local (9) and peritoneal and
local (4).
Statistical methods
Survival curves were constructed according to the Kaplan–Mayer
method and differences were analysed with the log-rank test.
Differences in proportions were evaluated with Fisher exact test. A
P-value below 0.05 was considered statistically significant.
RESULTS
Treatment effect
The median number of i.p. chemotherapy courses was 3 (1–8).
Four patients had pain during or immediately after the i.p.
infusion; however, none of the patients terminated the planned
treatment because of infusion-related pain. Leakage from the drain
site was noted in one patient. Two patients suffered repetitively
from nausea and vomiting during the i.p. treatment period, and
transient neutropenia was noted in one patient. Of the patients, 13
terminated the planned treatment prematurely, seven of them
because of catheter-related problems (local catheter infection (1),
improper position (1), obstruction (5)), ileus 1, liver metastases 1,
decline in general status 1 and two patients refused further
treatment. Single photon emission computed tomography studies
showed a median abdominal cavity distribution volume of 2896ml
(range 32–11557). In one patient, treatment was withdrawn after
SPECT because of the lack of widespread distribution in
abdominal cavity. In five patients the PORT-A-CATH was
reoperated. There was no mortality related to surgery or to the
i.p. treatment. In one patient who was not treated with
cytoreductive surgery, no i.p. chemotherapy was administered.
Survival
The median survival in i.p. patients was 32 months (95%
confidence interval (CI ) 22.2–62.6 months), whereas in the i.v.
control group it was 14 months (95% CI 5.6–24.9 months),
(P¼0.01, Figure 1). A 2 and 5 years survival in i.p. patients were 60
and 28%, whereas corresponding values in the i.v. control group
were 10 and 5%. In all, 11 patients who were considered
macroscopically tumour free after the tumour reduction procedure
had a longer survival (34.5 months, 95% CI 28.7–75.7) than those
who did not undergo macroscopically radical surgery (10 months,
95% CI  15.7 to 70.0), (P¼0.02, Figure 2). Five patients in whom
radical surgery could be performed are still alive (median 8.3 years,
range 6.8–9.1) after surgery. One patient who underwent radical
surgery survived only 4 months. One patient who was considered
not to be macroscopicallly tumor free after the tumor reduction
procedure is still alive and has survived 10.8 years. In total, 10
patients in whom radical surgery was not performed survived
median 13 months (range 3 months–10.8 years).
DISCUSSION
Our experience, with treatment of peritoneal colorectal metastases,
is promising. We believe patients without hematogenous metas-
tases (e.g. liver, lung, etc) from colorectal cancer might have a
survival benefit if cytoreductive surgery is combined with i.p.
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lTable 1 Surgical procedures of the 18 patients in the i.p. group
Preinclusion events Events at inclusion Postinclusive events
Pat.
Primary
tumour
site
Surgical
procedures at
primary
tumour
surgery
Completing
surgical
events before
inclusion Metastatic site at inclusion
Surgical
procedures at
inclusion
Macroscopically
radical
Remnant
tumour
location
Additional
surgical tumour
procedures
PAC
reop.
1 Colon Colectomy, IRA Rectal res. SBR 2 Small bowel, abdominal wall,
peritoneal
SBR, AWR, local excision Yes SBR Yes
2 Colon R. hemicolectomy Ventricle, duodenum, small
bowel 2
ICR, duodenal resection,
local excision, EC
Yes Yes
3 Colon Sigmoid resection, SOE Peritoneal Local excision, EC Yes No
4 Rectum APR Pelvic wall Local excision No Pelvic Scapula and costae
resection
No
5 Colon Ileocaecal resection Ileocolic anastomosis, jejunum,
abdominal wall
ICR, SBR, local excision Yes ICR 2, SBR, AWR Yes
6 Colon Sigmoid resection, L.
hemicolectomy, splenectomy
Abdominal wall, small bowel AWR, SBR, local excision Yes No
7 Colon Sigmoid resection
R. hemicolectomy
Ileocolic anastomosis ICR, local excision Yes R. hepatectomy, aorta
resection, SBR
No
8 Colon R. hemicolectomy Ileocolic anastomosis,
sigmoid, uterus, ovary,
vagina, peritoneal
ICR, local excision, SOE,
hysterectomy, EC
No Small bowel
(peritoneal)
sigmoid colon
(peritoneal)
SBR, rectosigmoid
resection,
ureterolysis
No
9 Colon L. hemicolectomy Colectomy+IRA,
SOE
Abdominal wall, pelvic wall,
peritoneal
AWR, local excision, EC No Pelvis Local excision, EC Yes
10 Colon R. hemicolectomy Pelvic wall, urinary bladder Urinary bladder
resection+urostoma,
local excision
No Pelvis No
11 Colon ICR Abdominal wall, ileocolic
anastomosis
R. hemicolectomy, AWR,
Local excision
Yes No
12 Colon Sigmoid resection Pelvic wall, rectum, small
bowel, L.A. iliaca int, L. ureter
AR, iliaca int resection,
local excision
Yes No
13 Colon R. hemicolectomy Abdominal wall, small bowel,
sigmoid colon
AWR, SBR, sigmoid
resection
Yes AWR No
14 Colon Ileocaecal resection R. colon, small bowel, ovary,
peritoneal
R. hemicolectomy,
SOE, local excision, EC.
Yes No
15 Rectum APR, sigmoideostoma Pelvic local, hepar, caecum ICR, Liver resection,
local excision
No Pelvis Yes
16 Colon Sigmoid resection, pelvic wall
resection
Ovary small bowel, colon
transversum, peritoneal
Transversum resection,
SBR, local
excision, EC.
Yes No
17 Colon Sigmoid resection Hartmann
resection, SBR
Peritoneal, locally advanced Local excision No Peritoneal Rectosigmoid
anastomosis
No
18 Colon R. hemicolectomy Peritoneal, locally advanced None No, No PAC Peritoneal, locally
advanced
AR¼anterior resection; SOE¼salpingo ofoor ectomy; APR¼anterior perineal resection; AWR¼abdominal wall resection; EC¼electric cautery; ICR¼ileocaecal resection; IRA¼ileorectal anastomosis; PAC¼port-A-cath;
SBR¼small bowel resection.
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Clinicalchemotherapy. Furthermore, a complete remission of the disease is
possible for an extended period of time. It seems that a
macroscopically radical tumour resection has an impact on
survival.
This series is not a prospective-randomised study, and a
selection of patients may of course have influenced the results.
However, in an attempt to compare the locoregional treatment to
standard i.v. chemotherapy, we used historical controls. The two
combinations (MFL and FLv) of chemotherapy, both based on
biochemical modulation of 5-FU, were equally effective with
respect to survival and response rates in one trial (Glimelius et al,
1998). It is therefore reasonable to consider these two combina-
tions as equal and these patients thus received ‘golden standard’
chemotherapy during their treatment period. However, the more
recently developed combination regimen (de Gramont et al, 2000;
Douillard et al, 2000; Saltz et al, 2000) are even more effective than
those used in the Nordic chemotherapy trials.
The relative importance of the i.p. chemotherapy cannot be
properly assessed in the present study and further studies are
needed to clarify a possible contribution of locoregional che-
motherapy to the treatment effect. A possible benefit of a repeated
regional treatment has been suggested since the end of 1960s (Long
et al, 1969) and several reports have been published since then
(Sugarbaker et al, 1996; Stephens et al, 1999; Cavaliere et al, 2000;
Elias et al, 2001). One of the major problems is the nonuniform
distribution of the chemotherapy to tumour deposits within the
abdominal cavity. The SPECTs can be valuable to analyse the drug
distribution in the abdominal cavity. If there are several adhesions,
the labelled albumin will accumulate only in a limited space and
chemotherapy may not reach all possible metastatic sites. To
prevent postoperative adhesions and an obliterated abdomen, an
early start of i.p. infusion, that is, immediately after surgery or at
the latest the first postoperative day may be important.
One of the concerns of i.p. chemotherapy is anastomotic
dehiscence. A study in humans indicated that it is possible to
give the present regimen a day after surgery without suppressing
the collagen accumulation too much (Graf et al, 1994a,b). In
addition, an experimental study showed an impaired healing after
i.p. 5-FU, but when folinic acid was added, no further deterioration
occurred (Graf et al, 1992). However, this problem and other
chemotherapy-related toxicities have been investigated in several
clinical studies and this form of administration has not been
associated with an increased complication rate (Graf et al, 1994c;
Vaillant et al, 2000).
The antitumoral effect of chemotherapy is believed to be
enhanced by hyperthermia (41–421C), possibly through an
increase in cell membrane permeability, alteration of active drug
transport, a change in cell metabolism and a decreased interstitial
fluid pressure (Hahn and Shiu, 1983; Leunig et al, 1992; Kong et al,
2000). Moreover, recent clinical studies have shown promising
results (Beaujard et al, 2000; Cavaliere et al, 2000). However, there
is a lack of consensus about the optimal target temperature and a
finding of increased morbidity and mortality when a cytoreduction
procedure has been followed by hyperthermic i.p. chemotherapy
(Jacquet et al, 1996) that warrant further studies. To optimise the
i.p. treatment, choosing the appropriate chemotherapy is crucial.
An important obstacle to successful treatment of solid tumours is
the resistance to cytotoxic drugs (Wright et al, 1998; Germann,
2000; Keppler et al, 2000). In this context, the drug resistance
examination is a potential valuable tool (Csoka et al, 1994, 1995).
In summary, a survival benefit can be achieved with cytor-
eductive surgery followed by repeated courses of i.p. chemother-
apy. A complete remission of the disease is possible for an
extended period of time. However, a longer period of follow-up is
needed to establish if definite cure is possible for this category of
patients and a randomised study is necessary to prove the value of
this approach definitely.
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